To evaluate the efficacy and tolerance of latanoprost in comparison with timolol for open angle glaucoma and ocular hypertension.
Two reviewers independently extracted the data using a standard form and resolved any disagreements by discussion. The data extracted were: author, year, study design, location, duration, the number of participants, age, gender, type of glaucoma and percentage withdrawals. For the latanoprost group and the timolol group in each study, the baseline mean IOP and the end point mean IOP were extracted along with their associated standard errors. The mean value of IOP measured in the morning, noon and afternoon was used in the analyses, except for one trial which only measured IOP in the morning. The data on local and systemic side-effects were extracted and the relative risk (RR), risk difference and the number-needed-to-harm (NNH) were estimated using intention-to-treat analysis. When the event rates were zero, 0.5 was added to each cell in the 2x2 table.
Methods of synthesis
How were the studies combined? A meta-analysis was used to pool the difference in the percentage reduction in IOP from baseline between latanoprost and timolol. The studies were weighted by the inverse of the variance (see Other Publications of Related Interest no.2). For adverse effects, the RR and risk difference were pooled using the method of DerSimonian and Laird (see Other Publications of Related Interest no.3). A random-effects model was used in the presence of unexplained statistical heterogeneity. The NNH and 95% confidence intervals (CIs) were estimated using the method of Cook and Sackett (see Other Publications of Related Interest no.4). Publication bias was not investigated.
How were differences between studies investigated?
The Q-statistic was used to assess statistical heterogeneity in the meta-analyses. Using the main efficacy outcome, differences between those studies that administered latanoprost in the evening, morning or twice daily were investigated by subgroup analyses that pooled individual treatment arms across the trials. Sensitivity analyses were conducted on the main efficacy outcome to look for differences by study design and withdrawal rates (greater than 10% versus less than 10%).
Results of the review
Eleven RCTs (n=1,256) were included.
The difference in the percentage reduction in IOP with latanoprost in comparison with timolol was 6.9 (95% CI: 0.4, 13.4) at one week (3 trials, n=81), 3.8 (95% CI: 1.2, 6.3) at one month (3 trials, n=524), 5.0 (95% CI: 2.8, 7.3) at 3 months (5 trials, n=841), and 5.0 (95% CI: 2.8, 7.3) at 6 months (4 trials, n=865). All differences were statistically significant. A random-effects model was apparently used to pool the data at one, 3 and 6 months because of statistical heterogeneity (p<0.001), but the tabulated information and the graph appeared to be inconsistent in that respect. Only one trial (n=36) provided data at 12 months (4.9, 95% CI: -5.9, 15.8) that showed no statistically-significant difference. The sensitivity analyses showed no statistical difference between the different study designs or between trials with greater than 10% versus less than 10% withdrawal rates.
Compared with timolol, the RR of hyperaemia was 2.2 (95% CI: 1.33, 3.65) and the NNH was 21 (95% CI: 14, 42) with latanoprost (6 trials, n=1,089). Iris pigmentation occurred in 21 of the 478 patients treated with latanoprost and in none of the 387 patients treated with timolol (4 trials; RR 8.0, 95% CI: 1.87, 34.3; NNH 36, 95% CI: 22, 91). No significant difference was shown for conjunctivitis (3 trials, n=739), hypotension (one trial, n=294) or bradycardia (one trial, n=178). Heterogeneity was not reported.
One trial (n=268) reported a reduction in heart rate of 4 beats per minute (bpm) (95% CI: 2, 6) at 3 and 6 months in the timolol group (p<0.01), compared with one bpm (95% CI: -2, 4) at 6 months in the latanoprost group. One other trial (n=294) showed no difference in bpm with timolol at 6 months.
One crossover trial compared an evening with a morning regimen of latanoprost. Only the first period data were considered, supposedly to reduce carryover effect, and these showed no statistically-significant difference in IOP reduction at 3 months (4.6%, standard error 2.6, p=0.08). The authors appear to have achieved a statistically-significant difference between the evening and morning regimens by pooling indirect comparisons.
Once-daily versus twice-daily latanoprost was not directly compared in any of the included trials. The authors appear to have pooled once-daily latanoprost data from three of the included trials with data from another RCT (n=50) that
